The CelluTome epidermal graft ‐harvesting system: a patient‐reported outcome measure and cost evaluation study

This study aimed to compare ESG with SSG by evaluating patient‐related outcome measures (PROMs) and the cost implications of both. Twenty patients answered a graft satisfaction questionnaire that evaluated: donor/graft site noticeability, aesthetic concerns, adverse problems and patient satisfaction. Cost/patient was calculated based on total operative expenses and five clinic follow‐ups. In 100% of the ESG cases, there were no DS noticeability or adverse problems compared to 25% in the SSG group. Complete satisfaction with DS appearance was observed in 100% of the ESG cases (50% SSG). Noticeability, adverse problems and overall satisfaction were significantly better in ESG cases (P < 0.05). Graft site parameters were comparable with similar healing outcomes. The cost per patient for ESG was £431 and £1489 for SSG, with an annual saving of £126 960 based on 10 grafts/month. For the right patient, CelluTome provides comparable wound healing, with reduced DS morbidity and higher patient satisfaction.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fiwj.12644

Source: International Wound Journal - August 3, 2016 Category: Surgery Authors: Oliver J Smith, Sarah ‐Jayne Edmondson, Nicki Bystrzonowski, Nadine Hachach‐Haram, Muholan Kanapathy, Toby Richards, Ash Mosahebi Tags: ORIGINAL ARTICLE Source Type: research